NEW YORK (GenomeWeb News) – Cepheid today said that it has received clearance from the US Food and Drug Administration to market its Xpert C. difficile test.

The Sunnyvale, Calif.-based molecular diagnostics firm said the test is designed to provide results in 45 minutes. It detects the bacterium that causes Clostridium difficile infection, a prevalent healthcare-associated infection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.